KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cost of Revenue (2021 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Cost of Revenue for 5 consecutive years, with $8.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 58.48% year-over-year to $8.8 million, compared with a TTM value of $32.7 million through Dec 2025, up 15.64%, and an annual FY2025 reading of $32.7 million, up 15.64% over the prior year.
  • Cost of Revenue was $8.8 million for Q4 2025 at Aurinia Pharmaceuticals, up from $8.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $8.9 million in Q2 2024 and bottomed at $48000.0 in Q1 2021.
  • Average Cost of Revenue over 5 years is $4.3 million, with a median of $5.4 million recorded in 2023.
  • The sharpest move saw Cost of Revenue skyrocketed 1741.33% in 2024, then fell 20.14% in 2025.
  • Year by year, Cost of Revenue stood at $481000.0 in 2021, then skyrocketed by 183.16% to $1.4 million in 2022, then soared by 296.11% to $5.4 million in 2023, then increased by 2.91% to $5.6 million in 2024, then surged by 58.48% to $8.8 million in 2025.
  • Business Quant data shows Cost of Revenue for AUPH at $8.8 million in Q4 2025, $8.2 million in Q3 2025, and $7.1 million in Q2 2025.